Hydrocodone/paracetamol - Grunenthal

Drug Profile

Hydrocodone/paracetamol - Grunenthal

Alternative Names: Acetaminophen/hydrocodone - Grunenthal; APAP/hydrocodone - Grunenthal; GRT7014; Hydrocodone/acetaminophen - Grunenthal; Hydrocodone/APAP - Grunenthal; Paracetamol/hydrocodone - Grunenthal

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Grunenthal
  • Class Acetanilides; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 19 Jul 2017 Grunenthal withdraws a phase I pharmacokinetic trial prior to enrolment due to the discontinued program in Healthy volunteers in USA (PO) (NCT03137030)
  • 19 Jul 2017 Grunenthal withdraws a phase I trial prior to enrolment due to the discontinued program in Healthy volunteers in USA (PO) (NCT03137017)
  • 01 May 2017 Phase-I clinical trials in Pain in USA (PO) (Intac pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top